Metformin, alfa-glucosidase inhibitors, thiazolidinediones, GLP1-receptor agonists, and SGLT2 inhibitors have proven efficacy in reducing the incidence of type 2 diabetes in subjects with prediabetes. Here, SLC5A2 is linked to prediabetes syndrome.